Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
43 Leser
Artikel bewerten:
(0)

GNC to be First to Launch Arnold Schwarzenegger Sports Nutrition Line

DENVER, Sept. 23, 2013 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, is proud to announce that the Arnold Series', an exclusive line of new nutritional supplements developed by Arnold Schwarzenegger and MusclePharm's world-renowned scientific team, will launch today on GNC.com and on October 1 in GNC stores. GNC Holdings, Inc. (NYSE: GNC) is the nation's largest specialty retailer of health and wellness products.

"GNC was the clear choice to launch the Arnold Series as they share our commitment to healthy living and they are such a highly-regarded retailer of health, wellness and sports nutrition products," said Brad Pyatt, founder and CEO, MusclePharm. "Arnold Schwarzenegger is idolized by fitness enthusiasts across the country so we turned to GNC with their large retail footprint to make the Arnold Series widely accessible."

"We are excited to be partnering withArnold Schwarzenegger and MusclePharm in the launch of this new line of sports nutrition products," said Joe Fortunato, President and CEO, GNC. "GNC's sports nutrition customers look to us for cutting-edge products that help in all of their training and workout needs. TheArnold Seriesis a great addition to our product line up."

MusclePharm's Arnold Series consists of eight sports nutrition products. Schwarzenegger worked side by side with MusclePharm's world-renowned scientific team to create a monumental line of new products that are revolutionary, safe-and above all-effective.

About MusclePharm Corporation:

MusclePharm® is an award-winning, worldwide leading sports nutrition company offering vitamins and nutritional supplementswhich areavailable in more than 110 countries and in over 11,000 U.S retail outlets.The company's brands are MusclePharm®, Arnold Schwarzenegger Series', and FitMiss'. The comprehensive lines of clinically-proven, safe and effective nutritional supplements address every element of the active, push-the-edge lifestyle-from muscle building and athletic performance to weight loss and general fitness.All MusclePharm productsare developed through a comprehensive six-stage research process that utilizes the expertise of leading nutritional scientists, doctors and universities.For more information, visitwww.musclepharm.comand follow @MusclePharm.

About GNC

GNC Holdings, Inc., headquartered in Pittsburgh, PA, is a leading global specialty retailer of health and wellness products, including vitamins, minerals, and herbal supplement products, sports nutrition products and diet products, and trades on the New York Stock Exchange under the symbol "GNC."

As of June 30, 2013, GNC has more than 8,300 locations, of which more than 6,200 retail locations are in the United States (including 969 franchise and 2,189 Rite Aid franchise store-within-a-store locations) and franchise operations in 55 countries (including distribution centers where retail sales are made). The Company - which is dedicated to helping consumers Live Well - has a diversified, multi-channel business model and derives revenue from product sales through company-owned retail stores, domestic and international franchise activities, third party contract manufacturing, e-commerce and corporate partnerships. GNC's broad and deep product mix, which is focused on high-margin, premium, value-added nutritional products, is sold under GNC proprietary brands, including Mega Men®, Ultra Mega®, Total Lean', Pro Performance®, Pro Performance® AMP, Beyond Raw®, and under nationally recognized third party brands.

Web:
GNC.coml Twitter: @GNCLiveWell l Facebook: facebook.com/GNCLiveWell

Forward Looking Statements

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

MusclePharm Contact:
Ivy Mollenkamp/Amy Pandya
Rogers & Cowan
310-854-8131/310-854-8262
imollenkamp@rogersandcowan.com
apandya@rogersandcowan.com

SOURCE MusclePharm Corporation

© 2013 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.